741 results about "Immune regulation" patented technology

Disclosed are methods, compositions of matter, and protocols useful for the induction of a therapeutic immune modulatory response through administration of exosomes derived from a stem cell source. In one embodiment, said stem cell source is endometrial regenerative cells. Specifically, in one embodiment stem cell derived exosomes are used as a method of treating an autoimmune condition such as rheumatoid arthritis, multiple sclerosis, or systemic lupus erythromatosis.

Disclosed are cells, methods of modulating cells, and therapeutic uses of the cells for the immune modulation of mammals in need thereof. Immune modulation including alteration of cytokine profile, cytotoxic activity, antibody production and inflammatory states is achieved through the administration of various cell types that have been unmanipulated or manipulated in order to endow specific biological activity. Cellular subsets and administration of the subsets in combination with various agents are also provided. One embodiment teaches the previously unknown finding that adipose tissue derived mononuclear cells contain T cells with immune regulatory properties that alone or synergistically with various stem cells induce immune modulation upon administration. Another embodiment is the finding that stimulation of stem cell activation results in stem cell secondary activation of immune modulatory cells, one type which is T regulatory cells (Tregs). One specific embodiment involves extraction of a heterogenous stem cell pool, which contains T regulatory cells, treatment in culture of the population with agents known to stimulate stem cell activation, then subsequent extraction and administration of the purified Tregs. Other embodiments include expansion of Tregs in the presence of antigen in order to generate anti-specific Tregs.

Methods and systems for the treatment for ALS incorporating stem cells harvested from the subject to be treated. These stem cells may be genetically altered with the addition of several genes of interest. Then, the patient will receive systemic gene therapy for the muscles and directed specifically at motor neurons. In this multi-pronged treatment approach, the stem cells provide immune regulation and the regeneration of motor neurons. And, the new motor neurons carry the added genes, which are protective against motor neuron death from ALS. The systemic therapy increases the amount of genes, which further reduces the effects of ALS. Additional gene therapy administered in the muscle will be further protective of the axon, while maintaining muscle mass and function.

Cancer therapies that combine epigenetic modulating agent(s) with immune modulating agent(s), which were remarkably identified to provide an improved treatment regimen over single agent therapy, are disclosed. In particular embodiments, the invention provides for improved treatment of NSCLC in patients via administration of exemplary immune modulating agents anti-PD-1 antibody or anti-PD-L1 antibody, which were observed to show enhanced activity in combination with the exemplary epigenetic modulating agent 5-deoxyazacytidine. Further, expression markers of responsive neoplastic cells are also disclosed.

The invention relates to TLR9 antagonist compounds and their therapeutic or prophylactic use. The invention provides novel immune regulatory oligonucleotides and immunomers as antagonist of TLRs and methods of use thereof. These immune regulatory oligonucleotides have unique sequences that suppress, without completely ablating, TLR-mediated signaling in response to a TLR ligand or TLR signaling agonist. The methods may have use in the prevention and treatment of autoimmunity, inflammation, inflammatory bowel disease, lupus, allergy, asthma, infection, sepsis, cancer and immunodeficiency.

The invention relates to lotus Fuzhuan brick tea and a preparation method thereof, in particular to a polymorphic and novel black tea preparation method by optimally combining genuine big leaf tea raw materials in Anhua (China) with medicinal and edible plants. The lotus Fuzhuan brick tea has the characteristics of black tea raw materials in local Anhua, ensures that the original ecological attributes of black tea products, has the obviously functions of nourishing yin to replenish the kidney, generating liquid to moisten dryness, nourishing yin to enrich fluid, regulating immune system, and has the obvious effects of tonifying the spleen to dispel wetness, smoothing qi for digesting and reducing blood lipid.

The invention provides a cell preparation for treating osteoarthritis and a preparation method thereof. The cell preparation mainly comprises mesenchymal stem cells, differentiation-induced stem cells, platelet-rich plasma and dispersion media thereof. Compared with the prior art, the cell preparation for treating osteoarthritis has the advantages that the mesenchymal stem cells are mixed with the differentiation-induced stem cells and compounded with the platelet-rich plasma and can be dispersed in the joint cavity, so that the immune regulation function of the mesenchymal stem cells can be exerted, the microenvironment of the whole joint cavity can be improved, and inflammation remission and injury repair are facilitated; tissues can be repaired after the differentiated mesenchymal stem cells are implanted into the body, so that the repair process is shortened.

Disclosed is a composition for administration to a human or animal subject, the composition containing spores of Bacillus subtilis in an amount effective to stimulate immune responsiveness in the subject. The spores have an adjuvant, immunomodulatory, immune potentiation, or dendritic cell maturation effect, or a combination thereof Also disclosed is a method of boosting an immune response in an animal subject by administering B. subtilis spores to an animal or human subject. Further disclosed is a vaccine containing B. subtilis spores, in the presence or absence of an antigen.

The present invention is related generally to embryonic-like stem cells isolated from human umbilical cord blood, designated herein as cord blood-stem cells (CB-SC's), which display the characteristics of embryonic stem cells and hematopoietic cells. These cells have the capability of proliferation and are able to differentiate to multiple types of cells. In addition, the CB-SC display low immunogenicity and immune regulation. These cells are, therefore, suitable for use in stem cell-based therapies for the treatment of diseases such as Parkinson's disease, diabetes, spinal cord damage, multiple sclerosis, cardiovascular disease, stroke and birth defects, and for preventing, treating and / or reducing an autoimmune disease in a mammalian subject.

The present invention discloses a method for extracting coix seed oil by using supercritical CO2 extraction process, and is characterized by that it makes the CO2 being in supercritical state by matched with entraining agent to implement extraction of coix seed, and its yield of coix seed oil can be up to above 8.18%. Said coix seed oil contains lots of unsaturated fatty acid and protein, can be used for preparing the medicine for curing cancer, making immune regulation, reducing blood fat, relieving inflammation and relieving cough, at the same time can be used for developing various function health-care foods.

The invention relates to a culture medium efficiently amplifying autologous NK cells and a culture method. The culture medium internally contains interleukin 2(IL-2), interleukin 15(IL-15), interleukin 7(IL-7), interleukin 12(IL-12), tumor necrosis factor alpha (TNFalpha) and CD3-antibody, can efficiently amplify and activate NK cells so as to obtain a large quantity of highly active immune cells with majority of NK cells to be transferred back to human bodies, and has remarkable curative effect in anti-tumor, anti-virus infection and immune adjustment related diseases. The culture medium efficiently amplifying autologous NK cells comprises the culture medium for cultivating cells and added factors added into the culture medium for cultivating cells, is used for cultivating and amplifying a large quantity of autologous activated NK cells, and is characterized in that the added factor comprises interleukin 2(IL-2), interleukin 15(IL-15), interleukin 7(IL-7), interleukin 12(IL-12), tumor necrosis factor alpha (TNF alpha) and CD3-antibody.

The invention discloses a giant salamander functional food with an immune regulation action and a preparation method thereof. The giant salamander functional food is prepared by obtaining giant salamander enzymatic hydrolysis powder by carrying out treatment of cell disruption, enzymatic hydrolysis and spray drying on giant salamander meat and then mixing the giant salamander enzymatic hydrolysis powder with extractive powder of medical and edible dual purpose plants including medlar, jujube and hawthorn and auxiliary materials according to a certain proportion. The preparation method keeps the nutrition activity of the giant salamander meat to the maximum extent, enhances the nutrition utilization ratio of a human body and also has the advantages of simple preparation process, convenient operation, safety, reliability, low production cost, and the like. The giant salamander meat functional food has the effects of eliminating oxygen free radicals, delaying aging and enhancing the immunity, is combined with the nourishing function of other medical and edible dual purpose plants so as to enhance the resistant ability of the human body to various diseases through long-term eating, strengthen the adaptability of the human body to the environment and be beneficial to the recovery of a patient after a surgery or with a weak constitution and is an ideal functional food.

Human extracellular ribonucleases (RNases) are widely distributed in various organs and body fluids and together with other members of the mammalian RNase A superfamily. In addition to their RNase activity, several RNases have been shown to have special biological actions, i.e., antitumor, antiviral and angiogenic properties. However, the molecular mechanisms of such activities are unclear. Using protein microarrays amplified rolling circle amplification (RCA), we investigated the effects of EDN (Rnase 2), ECP (Rnase 3) and RNase 1 on leukocytes cytokine production. We measured the levels of 78 different cytokines and growth factors in culture supernatants to determine the cytokine profiles of cells treated with different combinations of RNases and RNase inhibitors. Members of human ribonuclease family (such as Rnase 1, hEDN (Rnase 2) and Rnase 3) induced expression of certain sets of cytokines in human leukocytes, including ENA-78, EOT2, BLC, GDNF, 1309, IFN-alpha, IFN-gamma, IL-10, IL-12P40, IL-12p70, IL-13, IL-16, IL-18, IL-1beta, IL-1ra, IL-2Sra, IL-3, IL-6, IL-6sR, IL-7, IL-8, IP-10, MCP-1, MCP-2, MCP-3, MCSF, MIG, MDC, MIP-1alpha, MIP-1beta, MPIF-1, NAP-2, RANTES, sCD23, OSM, TARC, TNF-alpha, TNF-R1 and uPAR. Thus members of the Rnase superfamily are therapeutic targets for treatment of inflammatory diseases and clinical conditions. Inhibition or augmentation of Rnase expression is used to modulate the immune system and is beneficial for host defense against various diseases and is exploited as an adjuvant. The expression of Rnases is a diagnostic marker for inflammation related conditions and is used to determine various disease stages. In addition, expression of cytokines, chemokines, growth factors is used to monitor efficacy of Rnase-base therapies.

Compositions useful in treating immune modulated disease comprising an anticytokine antibody or immune active drug capable of modifying cytokine activity or modulating the immune system microencapsulated with a biodegradable nonantigenic material, such as albumin or PLGA. When the composition is introduced into a subject, it is phagocytosed by the target organ, the target organ digests the microsphere, releasing the drug or an active form or fragment thereof intracellularly. The drug then modifies the target organ function, thereby modulating it's activity. A method is disclosed for preparation of the microencapsulated composition.

The invention relates to bursa of Fabricius heptapeptide with immune regulation effect and application thereof in immunity (in improving the immune capability of animals, improving the immune effect of vaccines and affecting the activity of tumor cells), and belongs to the field of immunology. The molecular weight of the separated heptapeptide is 722.240, the amino acid sequence is EPASGMM, and the heptapeptide has a simple structure, no toxic or side effect and extremely weak immunogenic property. The heptapeptide can be separated and extracted from bursa of Fabricius, also can be chemically synthesized, has low cost, and can be massively produced. The bursa of Fabricius heptapeptide has induction effect on the production of antibody and subtype thereof, and meanwhile can regulate the production of cell factors, partition of T lymphocytes and proliferation of spleen cells, and promote the immune reaction of the cells. The bursa of Fabricius heptapeptide is an immune regulation factor on functions, has wide application prospect on the aspects of immune regulation, immune therapy and the like, and can be applied in the fields of basic immune research, clinical application research and the like.

The invention provides a hawthorn vinegar healthy beverage, which is characterized by comprising the following raw materials in weight portion: 40 to 80 portions of hawthorn, 40 to 80 portions of honey, 40 to 80 portions of xylitol, 50 to 100 portions of white vinegar, 0.25 to 0.5 portion of aspartame, and 650 to 850 portions of water, and the hawthorn vinegar is prepared by a certain method. The hawthorn vinegar has disease prevention efficacy of table vinegar, good flavor of juice, palateful sweet and sour and sweet taste, and is suitable to be directly drunk. The hawthorn vinegar is rich in various amino acids, organic acid, vitamin, mineral and other nutritious ingredients, and has efficacies of blood-fat reduction, vessel relaxing, oxidation resistance, immunity regulation, harmful bacteria elimination, balance maintenance for blood acid alkali, weight reduction, digestion help and sobering up and the like.

The invention provides a pig IFN (interferon) gamma-Fc fusion protein optimized according to a silkworm reaction system and a coding gene of the pig IFNgamma-Fc fusion protein and a method of expressing pig IFNgamma-Fc fusion protein by using a silkworm bioreactor, and belongs to the field of a biological genetic engineering. The pig interferon gamma serving as a non-special broad spectrum antiviral biological agent has a wide medicinal prospect in a veterinary drug field; but like most of genetic engineering veterinary drugs, the pig interferon gamma also has the problems such as insufficient output, expensive price, irregular quality, short acting time and the like. A target protein with a high expression efficiency and strong activity is obtained by expressing the pig IFNgamma-Fc fusion protein optimized by using a silkworm expression system. In addition, the acting time of the pig interferon gamma is prolonged by addition of an Fc segment, so that the overall immune regulation effect is enhanced, and purification at a later stage is facilitated, thus a pig IFNgamma-Fc fusion protein preparation produced by using a genetic engineering method is possible, and a condition is also created for developing a novel feed containing the fusion protein.

Disclosed are methods of treating subjects having disorders or conditions characterized by an unwanted immune response including administering an effective amount of an early activation molecule agonist, antagonist or depletor, to the subject. Human monoclonal antibodies specific to the early activation molecules, and methods of use, are also disclosed.

GM-CSF administered before immunization exerted a sustained suppressive effect against the induction of myasthenia gravis (MG). This suppression was associated with lowered serum autoantibody levels, reduced T cell proliferative responses to AChR, and an expansion in the population of FoxP3+ regulatory T cells. Manipulating DCs to expand regulatory T cells is useful for the control of autoimmune diseases such as myasthenia gravis MG.

The invention discloses a preparation method of human adipose-derived MSCs (mesenchymal stem cells) and an application of the human adipose-derived MSCs in preparation of medicine for treating diseases. The preparation method of the human adipose-derived MSCs comprises steps as follows: adipose tissue collection, adipose tissue transportation, adipose tissue connection, adipose tissue microblock preparation, SVF (stromal vascular fraction) extraction, primary culture, subculturing, cell cryopreservation, cell bank establishment and cell recovery. The human adipose-derived MSCs have a powerful immunity regulation function and can be applied to preparation of medicine for treating autoimmune diseases, and compared with conventional medicine, the human adipose-derived MSCs have the advantages as follows: 1, the treatment is convenient, the curative effect is lasting, the variety and the number of medicine for treatment and toxic and side effects caused by medicine treatment can be reduced, even the medicine such as immunosuppressant and the like for treatment is out of service, the death rate and the disability rate are reduced, and life quality is improved; 2, the safety is good, and toxic and side effects are avoided; 3, the source of adipose tissue is wide, the collection is convenient, fundamental research of the human adipose-derived MSCs is solid, the preparation technology is mature, the popularization degree is high, and the technology is controllable; and 4, the preparation cost of the human adipose-derived MSCs is lower than that of other biological preparation and can be accepted by most patients.

the invention discloses a preparing method of extracellular polysaccharide of Bacillus subtilis and application in the tumour facet, which is characterized by the following: inhibiting tumour from growing; accelerating the growth of macrophage, leucocyte and lymph cell; fitting for health or immune adjusting drug.

The invention provides the use of immune regulatory oligonucleotides (IRO) as antagonist of TLRs in the prevention and treatment of a disease caused by a pathogen, for example, a DNA or RNA virus.

The invention provides novel immune regulatory oligonucleotides (IRO) as antagonist of TLRs and methods of use thereof. These IROs have unique sequences that inhibit or suppress TLR-mediated signaling in response to a TLR ligand or TLR agonist. The methods may have use in the prevention and treatment of cancer, an autoimmune disorder, airway inflammation, inflammatory disorders, infectious disease, skin disorders, allergy, asthma or a disease caused by a pathogen.

The invention relates to the field of protein, in particular to a bioactive peptide SKVLPVPEKAVPYPQ as well as a preparation method and an application thereof. An amino acid sequence of the bioactive peptide SKVLPVPEKAVPYPQ is Ser-Lys-Val-Leu-Pro-Val-Pro-Glu-Lys-Ala-Val-Pro-Tyr-Pro-Gln. An in-vitro anti-oxidation experiment and an in-vitro immunity function promoting experiment prove that the bioactive peptide SKVLPVPEKAVPYPQ has better anti-oxidation biological activity and immunity regulation function, on one hand, the bioactive peptide SKVLPVPEKAVPYPQ has better anti-oxidation activity, can clear free radicals in an organism and improves life quality; on the other hand, by the aid of the bioactive peptide SKVLPVPEKAVPYPQ, in-vitro proliferation capacity of lymphocytes and macrophages can be enhanced, the phagocytosis capacity of the macrophages for neutral red is improved, the organism's capacity of resisting outside pathogen infection is improved, morbidity of the organism is reduced, and therefore, the bioactive peptide SKVLPVPEKAVPYPQ has quite great significance in development of food, healthcare products and drugs with an immune regulation function and an anti-oxidation function.

The present invention relates to the field of protein, and in particular relates to biologically active polypeptide WNIPMGLIVNQ and a preparation method and the application thereof, and the amino acid sequence of the biologically active polypeptide WNIPMGLIVNQ is Trp-Asn-Ile-Pro-Met-Gly-Leu-Ile-Val-Asn-Gln. In vitro antioxidant experiments and in vitro immune function promotion experiments verify the biologically active polypeptide WNIPMGLIVNQ has good antioxidant biological activity and immunity regulating function, on the one hand, the biologically active polypeptide WNIPMGLIVNQ has good antioxidant activity to remove free radicals in the body and improve the quality of life; on the other hand, the biologically active polypeptide WNIPMGLIVNQ can enhance the in-vitro proliferation ability of lymphocytes and macrophages to promote the increase of macrophage induced nitric oxide, the biologically active polypeptide WNIPMGLIVNQ can improve the external pathogen infection resistance of the body and reduce the disease incidence of the body, and has very important significance for development of food, health care products and drugs with immune function regulating and antioxidant function.